Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer.

Ohmura H, Ito M, Uchino K, Okada C, Tanishima S, Yamada Y, Momosaki S, Komoda M, Kuwayama M, Yamaguchi K, Okumura Y, Nakano M, Tsuchihashi K, Isobe T, Ariyama H, Kusaba H, Oda Y, Akashi K, Baba E.

FEBS Open Bio. 2020 Jan;10(1):147-157. doi: 10.1002/2211-5463.12765. Epub 2019 Dec 3.

2.

Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil.

Moriyama S, Yokoyama T, Irie K, Ito M, Tsuchihashi K, Fukata M, Kusaba H, Maruyama T, Akashi K.

J Cardiol Cases. 2019 Aug 23;20(5):183-186. doi: 10.1016/j.jccase.2019.08.005. eCollection 2019 Nov.

3.

Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients.

Takayoshi K, Kusaba H, Aikawa T, Koreishi S, Sagara K, Nakano M, Komoda M, Kono M, Fukata M, Arita T, Esaki T, Akashi K, Baba E.

Gastric Cancer. 2019 Sep;22(5):988-998. doi: 10.1007/s10120-019-00930-2. Epub 2019 Feb 20.

PMID:
30788749
4.

Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.

Yoshihiro T, Kusaba H, Makiyama A, Kobayashi K, Uenomachi M, Ito M, Doi Y, Mitsugi K, Aikawa T, Takayoshi K, Esaki T, Shimokawa H, Tsuchihashi K, Ariyama H, Akashi K, Baba E.

Int J Clin Oncol. 2019 May;24(5):508-515. doi: 10.1007/s10147-018-01391-w. Epub 2019 Jan 2.

PMID:
30604155
5.

Metastatic esophageal carcinosarcoma comprising neuroendocrine carcinoma, squamous cell carcinoma, and sarcoma: A case report.

Tsuchihashi K, Arita S, Fujiwara M, Iwasaki K, Hirano A, Yoshihiro T, Nio K, Koga Y, Esaki M, Ariyama H, Kusaba H, Moriyama T, Ohuchida K, Nagai E, Nakamura M, Oda Y, Akashi K, Baba E.

Medicine (Baltimore). 2018 Oct;97(41):e12796. doi: 10.1097/MD.0000000000012796.

6.

PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer.

Nakano M, Ito M, Tanaka R, Yamaguchi K, Ariyama H, Mitsugi K, Yoshihiro T, Ohmura H, Tsuruta N, Hanamura F, Sagara K, Okumura Y, Nio K, Tsuchihashi K, Arita S, Kusaba H, Akashi K, Baba E.

Cancer Sci. 2018 Sep;109(9):2986-2992. doi: 10.1111/cas.13723.

7.

Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer.

Nakano M, Kikushige Y, Miyawaki K, Kunisaki Y, Mizuno S, Takenaka K, Tamura S, Okumura Y, Ito M, Ariyama H, Kusaba H, Nakamura M, Maeda T, Baba E, Akashi K.

Oncogene. 2019 Feb;38(6):780-793. doi: 10.1038/s41388-018-0480-0. Epub 2018 Sep 4.

PMID:
30181548
8.

Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer.

Nakano M, Ito M, Tanaka R, Ariyama H, Mitsugi K, Makiyama A, Uchino K, Esaki T, Tsuruta N, Hanamura F, Yamaguchi K, Okumura Y, Sagara K, Takayoshi K, Nio K, Tsuchihashi K, Tamura S, Shimokawa H, Arita S, Miyawaki K, Kusaba H, Akashi K, Baba E.

Cancer Sci. 2018 Nov;109(11):3461-3470. doi: 10.1111/cas.13777. Epub 2018 Sep 27.

9.

Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody.

Yamaguchi K, Mishima K, Ohmura H, Hanamura F, Ito M, Nakano M, Tsuchihashi K, Ota SI, Wada N, Uchi H, Ariyama H, Kusaba H, Niiro H, Akashi K, Baba E.

Cancer Sci. 2018 Oct;109(10):3032-3042. doi: 10.1111/cas.13758. Epub 2018 Aug 31.

10.

The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer.

Yamaguchi K, Kusaba H, Makiyama A, Mitsugi K, Uchino K, Tamura S, Shibata Y, Esaki T, Ito M, Takayoshi K, Tsuchihashi K, Arita S, Ariyama H, Akashi K, Baba E.

Cancer Chemother Pharmacol. 2018 Oct;82(4):625-633. doi: 10.1007/s00280-018-3652-2. Epub 2018 Jul 24.

PMID:
30043209
11.

A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy.

Kumagai H, Kusaba H, Yamanaka T, Nio K, Inadomi K, Takayoshi K, Ito M, Tamura S, Makiyama A, Makiyama C, Hirano G, Shibata Y, Shirakawa T, Mitsugi K, Ariyama H, Esaki T, Akashi K, Baba E.

Medicine (Baltimore). 2018 Jun;97(25):e11042. doi: 10.1097/MD.0000000000011042.

12.

E‑cadherin regulates proliferation of colorectal cancer stem cells through NANOG.

Tamura S, Isobe T, Ariyama H, Nakano M, Kikushige Y, Takaishi S, Kusaba H, Takenaka K, Ueki T, Nakamura M, Akashi K, Baba E.

Oncol Rep. 2018 Aug;40(2):693-703. doi: 10.3892/or.2018.6464. Epub 2018 May 24.

13.

Successful chemotherapeutic treatment for metastatic littoral cell angioma: A case report.

Takayoshi K, Doi G, Tsuruta N, Yoshihiro T, Nio K, Tsuchihashi K, Ariyama H, Odawara J, Shimoda S, Kohashi K, Oda Y, Itoh S, Harimoto N, Maehara Y, Kusaba H, Akashi K, Baba E.

Medicine (Baltimore). 2018 Apr;97(15):e0378. doi: 10.1097/MD.0000000000010378.

14.

Metastatic esophageal cancer presenting as shock by injury of vagus nerve mimicking baroreceptor reflex: A case report.

Tsuchihashi K, Yoshihiro T, Aikawa T, Nio K, Takayoshi K, Yokoyama T, Fukata M, Arita S, Ariyama H, Shimizu Y, Yoshida Y, Torisu T, Esaki M, Odashiro K, Kusaba H, Akashi K, Baba E.

Medicine (Baltimore). 2017 Dec;96(49):e8987. doi: 10.1097/MD.0000000000008987.

15.

Lingual alveolar soft part sarcoma responsive to pazopanib: A case report.

Yoshihiro T, Tsuchihashi K, Nio K, Arita S, Nakano T, Yasumatsu R, Jiroumaru R, Ariyama H, Kusaba H, Oda Y, Akashi K, Baba E.

Medicine (Baltimore). 2017 Nov;96(44):e8470. doi: 10.1097/MD.0000000000008470.

16.

Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report.

Tsuchihashi K, Shimokawa H, Takayoshi K, Nio K, Aikawa T, Matsushita Y, Wada I, Arita S, Ariyama H, Kusaba H, Sonoda KH, Akashi K, Baba E.

Medicine (Baltimore). 2017 Oct;96(42):e8285. doi: 10.1097/MD.0000000000008285. Erratum in: Medicine (Baltimore). 2017 Nov 03;96(44):e8576.

17.

Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer.

Ito M, Kusaba H, Mukaide S, Kishimoto J, Shimokawa H, Tamura S, Makiyama A, Hirano G, Oda H, Shirakawa T, Komoda M, Uchino K, Tanaka R, Mitsugi K, Esaki T, Arita S, Ariyama H, Akashi K, Baba E.

Anticancer Drugs. 2017 Nov;28(10):1166-1173. doi: 10.1097/CAD.0000000000000562.

PMID:
28906258
18.

Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer.

Makiyama A, Arimizu K, Hirano G, Makiyama C, Matsushita Y, Shirakawa T, Ohmura H, Komoda M, Uchino K, Inadomi K, Arita S, Ariyama H, Kusaba H, Shinohara Y, Kuwayama M, Kajitani T, Oda H, Esaki T, Akashi K, Baba E.

Gastric Cancer. 2018 May;21(3):464-472. doi: 10.1007/s10120-017-0759-9. Epub 2017 Aug 10.

PMID:
28799048
19.

Systemic chemotherapy with pronounced efficacy and neutropenia in a granulocyte-colony stimulating factor-producing advanced gastric neuroendocrine carcinoma.

Tsuruta N, Takayoshi K, Arita S, Aikawa T, Ariyama H, Kusaba H, Ohuchida K, Nagai E, Kohashi K, Hirahashi M, Inadomi K, Tanaka M, Sagara K, Okumura Y, Nio K, Nakano M, Nakamura M, Oda Y, Akashi K, Baba E.

Oncol Lett. 2017 Aug;14(2):1500-1504. doi: 10.3892/ol.2017.6299. Epub 2017 Jun 2.

20.

Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.

Takayoshi K, Kusaba H, Uenomachi M, Mitsugi K, Makiyama C, Makiyama A, Uchino K, Shirakawa T, Shibata Y, Shinohara Y, Inadomi K, Tsuchihashi K, Arita S, Ariyama H, Esaki T, Akashi K, Baba E.

Cancer Chemother Pharmacol. 2017 Aug;80(2):333-342. doi: 10.1007/s00280-017-3371-0. Epub 2017 Jun 26.

PMID:
28653251
21.

Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case report.

Yoshihiro T, Nio K, Tsuchihashi K, Ariyama H, Kohashi K, Tsuruta N, Hanamura F, Inadomi K, Ito M, Sagara K, Okumura Y, Nakano M, Arita S, Kusaba H, Oda Y, Akashi K, Baba E.

Mol Clin Oncol. 2017 Jun;6(6):866-870. doi: 10.3892/mco.2017.1240. Epub 2017 May 5.

22.

Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans.

Tsuchihashi K, Kusaba H, Yamada Y, Okumura Y, Shimokawa H, Komoda M, Uchino K, Yoshihiro T, Tsuruta N, Hanamura F, Inadomi K, Ito M, Sagara K, Nakano M, Nio K, Arita S, Ariyama H, Kohashi K, Tominaga R, Oda Y, Akashi K, Baba E.

Mol Clin Oncol. 2017 May;6(5):665-668. doi: 10.3892/mco.2017.1197. Epub 2017 Mar 17.

23.

Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer.

Inadomi K, Kusaba H, Matsushita Y, Tanaka R, Mitsugi K, Arimizu K, Hirano G, Makiyama A, Ohmura H, Uchino K, Hanamura F, Shibata Y, Kuwayama M, Esaki T, Takayoshi K, Arita S, Ariyama H, Akashi K, Baba E.

Anticancer Res. 2017 May;37(5):2663-2671.

PMID:
28476842
24.

Cardiac metastasis of squamous cell carcinoma of the thyroid gland with severe disseminated intravascular coagulation: A case report.

Yoshihiro T, Tsuchihashi K, Kusaba H, Nakashima T, Obara T, Nio K, Takayoshi K, Kodama H, Tsuruta N, Kiyohara H, Asai K, Harada E, Kamezaki K, Arita T, Sato M, Yamamoto H, Arita S, Ariyama H, Odashiro K, Oda Y, Akashi K, Baba E.

Mol Clin Oncol. 2017 Jan;6(1):91-95. doi: 10.3892/mco.2016.1091. Epub 2016 Nov 23.

25.

Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.

Kusaba H, Kumagai H, Inadomi K, Matsunobu T, Harimaya K, Takayoshi K, Arita S, Ariyama H, Akashi K, Baba E.

Medicine (Baltimore). 2016 Dec;95(49):e5460.

26.

Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report.

Inadomi K, Kumagai H, Arita S, Tsuruta N, Takayoshi K, Mishima K, Ota S, Tanaka M, Okumura Y, Sagara K, Nio K, Nakano M, Uchi H, Yamamoto H, Ariyama H, Kusaba H, Niiro H, Oda Y, Akashi K, Baba E.

Medicine (Baltimore). 2016 Jul;95(29):e4283. doi: 10.1097/MD.0000000000004283.

27.

Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients.

Shirakawa T, Nakano M, Nio K, Tamura S, Komoda M, Kumagai H, Uchino K, Odashiro K, Arita S, Shibata Y, Ariyama H, Kusaba H, Akashi K, Baba E.

Anticancer Drugs. 2016 Oct;27(9):891-8. doi: 10.1097/CAD.0000000000000392.

PMID:
27272413
28.

Comparison of nerve regenerative efficacy between decellularized nerve graft and nonwoven chitosan conduit.

Kusaba H, Terada-Nakaishi M, Wang W, Itoh S, Nozaki K, Nagai A, Ichinose S, Takakuda K.

Biomed Mater Eng. 2016 May 12;27(1):75-85. doi: 10.3233/BME-161571.

PMID:
27175469
29.

Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.

Arita S, Shirakawa T, Matsushita Y, Shimokawa HK, Hirano G, Makiyama A, Shibata Y, Tamura S, Esaki T, Mitsugi K, Ariyama H, Kusaba H, Akashi K, Baba E.

Anticancer Res. 2016 Apr;36(4):1959-66.

PMID:
27069187
30.

Intraluminal superior vena cava metastasis from adenosquamous carcinoma of the duodenum: A case report.

Takayoshi K, Ariyama H, Tamura S, Yoda S, Arita T, Yamaguchi T, Ozono K, Yamamoto H, Inadomi K, Kumagai H, Tanaka M, Okumura Y, Sagara K, Nio K, Nakano M, Arita S, Kusaba H, Odashiro K, Oda Y, Akashi K, Baba E.

Oncol Lett. 2016 Jan;11(1):605-609. Epub 2015 Nov 18.

31.

Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: A case report.

Kuwayama M, Uchino K, Takayoshi K, Komoda M, Kohjima M, Nakamuta M, Momosaki S, Kusaba H, Akashi K, Baba E.

Oncol Lett. 2016 Jan;11(1):85-88. Epub 2015 Nov 2.

32.

Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan.

Nio K, Higashi D, Kumagai H, Arita S, Shirakawa T, Nakashima K, Shibata Y, Esaki M, Manabe T, Nagai S, Ueki T, Nakano M, Ariyama H, Kusaba H, Hirahashi M, Oda Y, Esaki T, Mitsugi K, Futami K, Akashi K, Baba E.

Anticancer Drugs. 2016 Jun;27(5):457-63. doi: 10.1097/CAD.0000000000000338.

PMID:
26771865
33.

Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case report.

Inadomi K, Kumagai H, Takayoshi K, Ariyama H, Kusaba H, Nishie A, Yamamoto H, Takase K, Tanaka M, Sagara K, Okumura Y, Nio K, Nakano M, Arita S, Oda Y, Akashi K, Baba E.

Oncol Lett. 2015 Nov;10(5):2981-2985. Epub 2015 Sep 16.

34.

A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.

Takayoshi K, Sagara K, Uchino K, Kusaba H, Sakamoto N, Iguchi A, Baba E.

BMC Cancer. 2015 May 22;15:426. doi: 10.1186/s12885-015-1443-2.

35.

[Anti-vascular endothelial growth factor antibody].

Kumagai H, Kusaba H, Baba E.

Nihon Rinsho. 2015 Feb;73 Suppl 2:229-34. Japanese. No abstract available.

PMID:
25831758
36.

[Platinum drugs].

Kusaba H, Baba E.

Nihon Rinsho. 2015 Feb;73 Suppl 2:143-5. Japanese. No abstract available.

PMID:
25831739
37.

Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.

Nio K, Arita S, Isobe T, Kusaba H, Kohashi K, Kajitani T, Tamura S, Hirano G, Mitsugi K, Makiyama A, Esaki T, Ariyama H, Oda Y, Akashi K, Baba E.

Cancer Chemother Pharmacol. 2015 Apr;75(4):829-35. doi: 10.1007/s00280-015-2706-y. Epub 2015 Feb 22.

PMID:
25702050
38.

Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.

Hirano G, Makiyama A, Makiyama C, Esaki T, Oda H, Uchino K, Komoda M, Tanaka R, Matsushita Y, Mitsugi K, Shibata Y, Kumagai H, Arita S, Ariyama H, Kusaba H, Akashi K, Baba E.

Anticancer Res. 2015 Jan;35(1):371-7.

PMID:
25550574
39.

Successful chemoradiotherapy for undifferentiated malignant neoplasm arising from the left pulmonary artery.

Kumagai H, Nio K, Okumura Y, Komoda M, Shirakawa T, Kusaba H, Yasuda S, Odashiro K, Arita S, Ariyama H, Yamada Y, Yamamoto H, Oda Y, Nakamura K, Akashi K, Baba E.

Case Rep Oncol. 2014 Jul 16;7(2):484-90. doi: 10.1159/000365387. eCollection 2014 May.

40.

Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).

Hironaka S, Tsubosa Y, Mizusawa J, Kii T, Kato K, Tsushima T, Chin K, Tomori A, Okuno T, Taniki T, Ura T, Matsushita H, Kojima T, Doki Y, Kusaba H, Fujitani K, Taira K, Seki S, Nakamura T, Kitagawa Y; Japan Esophageal Oncology Group/Japan Clinical Oncology Group.

Cancer Sci. 2014 Sep;105(9):1189-95. doi: 10.1111/cas.12486.

41.

Favorable control of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma with multimodality therapy: a case report.

Sagara K, Takayoshi K, Kusumoto E, Uchino K, Matsumura T, Kusaba H, Momosaki S, Ikejiri K, Baba E.

BMC Res Notes. 2014 Jun 19;7:377. doi: 10.1186/1756-0500-7-377.

42.

Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan.

Isobe T, Uchino K, Makiyama C, Ariyama H, Arita S, Tamura S, Komoda M, Kusaba H, Shirakawa T, Esaki T, Mitsugi K, Takaishi S, Akashi K, Baba E.

Anticancer Res. 2014 Apr;34(4):2035-40.

PMID:
24692744
43.

Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan.

Kumagai H, Kusaba H, Okumura Y, Komoda M, Nakano M, Tamura S, Uchida M, Nagata K, Arita S, Ariyama H, Takaishi S, Akashi K, Baba E.

Asian Pac J Cancer Prev. 2014;15(1):461-5.

44.

Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer.

Tamura S, Kusaba H, Kubo N, Ijichi K, Tsuchihashi K, Komoda M, Uchino K, Ariyama H, Akashi K, Baba E.

Med Oncol. 2014 Mar;31(3):856. doi: 10.1007/s12032-014-0856-0. Epub 2014 Jan 30.

PMID:
24477650
45.

Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.

Nakano M, Kusaba H, Makiyama A, Ariyama H, Arita S, Oda H, Esaki T, Takayoshi K, Uchino K, Tamura S, Kumagai H, Iwama E, Shirakawa T, Mitsugi K, Takaishi S, Akashi K, Baba E.

Anticancer Res. 2014 Jan;34(1):215-20.

PMID:
24403465
46.

[Development trends for therapeutic antibody].

Baba E, Kusaba H, Nakano S.

Nihon Rinsho. 2012 Dec;70(12):2098-103. Review. Japanese.

PMID:
23259380
47.

Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.

Kusaba H, Esaki T, Kishimoto J, Uchino K, Arita S, Kumagai H, Mitsugi K, Akashi K, Baba E.

Cancer Chemother Pharmacol. 2013 Jan;71(1):29-34. doi: 10.1007/s00280-012-2023-7. Epub 2012 Dec 11.

PMID:
23228984
48.
49.

Improvement of quality of life and survival using self-expandable metal stent placement for severe malignant stenosis of the gastric body: a case report.

Kumagai H, Nio K, Shirakawa T, Uchino K, Kusaba H, Isobe T, Komoda M, Tamura S, Maeyama R, Nagai E, Akashi K, Baba E.

J Med Case Rep. 2012 Sep 19;6:315. doi: 10.1186/1752-1947-6-315.

50.

Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.

Iwasa S, Goto M, Yasui H, Nishina T, Takahari D, Nakayama N, Taira K, Kusaba H, Fuse N, Hironaka S, Shimada Y, Nakajima TE.

Jpn J Clin Oncol. 2012 Sep;42(9):787-93. doi: 10.1093/jjco/hys111. Epub 2012 Jul 10.

PMID:
22782960

Supplemental Content

Loading ...
Support Center